Loading
Life sciences · Journal article
Ejnmmi Research · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Accurate preoperative assessment of pathological response to neoadjuvant therapy (NAT) in rectal cancer remains challenging, particularly after immunotherapy. This study aimed to explore the feasibility of using post-treatment [ 18 F]-FDG and [ 18 F]-FAPI-42 PET/MRI to detect pathological response. Thirty-six patients with locally advanced rectal cancer who completed short-course radiotherapy followed by immunochemotherapy were prospectively enrolled. After 28 days, paired PET/MRI and dynamic contrast-enhanced MRI were performed, followed by surgery within one week. Combined PET/MRI interpretation achieved significantly higher accuracy for predicting tumor regression grade (TRG) (75.00%) and pathological complete response (pCR) (86.11%) than PET or MRI alone (all P < 0.05), with substantial agreement with pathology (κ = 0.66 for TRG; κ = 0.68 for pCR). [ 18 F]-FAPI-42 PET provided more parameters differentiating TRG groups than [ 18 F]-FDG PET. The FAPI-SUVmax/FDG-SUVmax ratio differed significantly between pCR and non-pCR groups ( P = 0.004) and showed good diagnostic performance for pCR (AUC = 0.82); a cutoff of 1.25 yielded 65% sensitivity and 92% specificity. Among MRI parameters, the time-intensity curve (TIC) outperformed ADC in predicting pCR (AUC 0.84 vs. 0.38). Post-treatment [ 18 F]-FDG and [ 18 F]-FAPI-42 PET/MRI effectively evaluate pathological response to NAT in rectal cancer. The FAPI-SUVmax/FDG-SUVmax ratio is a promising imaging biomarker for identifying pCR, potentially guiding surgery de-escalation. NCT06318234. https://clinicaltrials.gov/study/NCT06318234.